360 Participants Needed

Lebrikizumab for Eczema

(ADorable-1 Trial)

Recruiting at 118 trial locations
Tm
SF
AH
Seth B. Forman, MD - ForCare Dermatology
Overseen BySeth Benjamin Forman
Age: < 18
Sex: Any
Trial Phase: Phase 3
Sponsor: Eli Lilly and Company
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does mention that you should not have used certain investigational drugs or Dupilumab recently. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug Lebrikizumab for eczema?

Research shows that Lebrikizumab, a drug targeting a protein called interleukin-13, is effective in treating moderate-to-severe eczema. In clinical trials, many patients experienced significant improvements in their skin condition and itchiness, with a good safety profile.12345

Is lebrikizumab safe for treating eczema?

Lebrikizumab has been shown to be generally safe in clinical trials for moderate-to-severe eczema, with most patients experiencing no significant side effects. Common mild side effects included conjunctivitis (eye inflammation), nasopharyngitis (cold-like symptoms), and headache.12345

What makes the drug Lebrikizumab unique for treating eczema?

Lebrikizumab is unique because it is a monoclonal antibody that specifically targets interleukin-13 (IL-13), a protein involved in the inflammation and skin barrier dysfunction seen in eczema. This targeted approach helps reduce symptoms like itching and skin lesions, offering a promising option for those with moderate-to-severe atopic dermatitis.12345

Research Team

C1

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for kids aged 6 months to less than 18 years with moderate-to-severe atopic dermatitis (eczema). They must have had eczema for a certain time and meet specific severity scores. Kids can't join if they've used experimental skin treatments recently, been in another study, or received certain vaccines or drugs too close to the start of this trial.

Inclusion Criteria

Your IGA score is 3 or higher during the screening and baseline.
You have a skin condition with an EASI score of 16 or higher at the screening and baseline.
I have been diagnosed with atopic dermatitis for the required time based on my age.
See 1 more

Exclusion Criteria

I have not taken Dupilumab in the last 8 weeks.
I received a BCG vaccine or treatment less than 4 weeks ago.
I haven't taken any experimental drugs recently.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive lebrikizumab or placebo by subcutaneous injections with a topical corticosteroid, dosing based on weight

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Lebrikizumab
  • Placebo
  • Topical corticosteroid
Trial OverviewThe study tests Lebrikizumab's effects on young patients with eczema compared to a placebo, alongside standard eczema creams. It aims to see how safe it is and how their bodies handle it.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Lebrikizumab (Cohort 2)Experimental Treatment2 Interventions
Participants who are 6 months to \<6 years of age, 2 years to \<6 years of age or 6 months to \<2 years of age will receive a loading dose of lebrikizumab and then subsequent doses by SC injections with a TCS. Dosing will be based on weight.
Group II: Lebrikizumab (Cohort 1)Experimental Treatment2 Interventions
Participants who are 6 years to \<18 years of age, 12 years to \<18 years of age who weigh \<40 kilogram (kg) or 6 years to \<12 years of age (may weigh ≥40 kg) will receive a loading dose and then subsequent doses by subcutaneous (SC) injections with a topical corticosteroid (TCS). Dosing will be based on weight.
Group III: PlaceboPlacebo Group2 Interventions
Participants will receive placebo matching lebrikizumab by SC injections with a TCS.

Lebrikizumab is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Ebglyss for:
  • Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg
🇺🇸
Approved in United States as Ebglyss for:
  • Moderate-to-severe atopic dermatitis in adults and children 12 years and older who weigh at least 88 pounds (40 kg)
🇨🇦
Approved in Canada as Ebglyss for:
  • Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eli Lilly and Company

Lead Sponsor

Trials
2,708
Recruited
3,720,000+
Dr. Daniel Skovronsky profile image

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks profile image

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University

Dermira, Inc.

Industry Sponsor

Trials
17
Recruited
6,100+

Findings from Research

In a 52-week Phase 3 study involving 206 adolescents with moderate-to-severe atopic dermatitis, lebrikizumab demonstrated a favorable safety profile, with only 2.4% of patients experiencing serious adverse events and the same percentage discontinuing treatment due to adverse events.
Lebrikizumab significantly improved atopic dermatitis symptoms, with 62.6% of patients achieving a 2-point improvement in the Investigator's Global Assessment and 81.9% achieving at least a 75% improvement in the Eczema Area and Severity Index by Week 52.
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.Paller, AS., Flohr, C., Eichenfield, LF., et al.[2023]
In a phase III trial, 74% of adults with moderate to severe atopic dermatitis (AD) treated with lebrikizumab 250 mg every 4 weeks showed significant improvement, achieving an Investigator Global Assessment score of 0/1, indicating effective treatment.
Lebrikizumab was associated with relatively mild side effects, with common adverse effects including conjunctivitis (7-8%), nasopharyngitis (4-5%), and headache (3-5%), suggesting it may be a safe long-term option for AD management.
The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.Prajapati, S., Fardos, M., Desai, AD., et al.[2023]
In a phase 3 trial involving 211 patients with moderate-to-severe atopic dermatitis, lebrikizumab (LEB) combined with topical corticosteroids (TCS) significantly improved skin condition, with 41.2% of patients achieving a clear or almost clear skin score compared to 22.1% in the placebo group.
The safety profile of LEB was consistent with previous studies, with most adverse events being mild or moderate, and serious adverse events were similarly low in both the LEB and placebo groups, indicating that LEB is a safe and effective treatment option.
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).Simpson, EL., Gooderham, M., Wollenberg, A., et al.[2023]

References

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study. [2023]
The role of lebrikizumab in the treatment of atopic dermatitis in the adult population. [2023]
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). [2023]
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis. [2023]
The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. [2023]